Forma sees data 'supporting' sickle cell therapy dosing levels; LianBio teams with Tarsus for eye irritation in China
Looking to make a splash in sickle cell, Forma Therapeutics presented new data they hope can improve their shot at an eventual FDA OK.
As part of an ongoing Phase I study, Forma said its FT-4202 program showed enough hemoglobin increases to support the doses selected in the upcoming Phase II/III trial, which is currently enrolling. Data from two cohorts illustrated 10 of 14 patients taking the once-daily therapy saw a hemoglobin increase of at least 1 g/dL from baseline over the two-week treatment period.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.